Structure-based design was used to develop a focused library of A-ring modified diphenyl ether InhA inhibitors. From this library of analogs, two high affinity alkyl-substituted diphenyl ethers, 6PP and 8PP, were selected for advanced study into their in vitro activity against Mycobacterium tuberculosis clinical isolates, their in vivo properties, and their signature response-mode of action profiles. 6PP and 8PP demonstrated enhanced activity against whole bacteria and showed activity in a rapid macrophage model of infection. In addition, transcriptional profiling revealed that the A-ring modifications of 6PP and 8PP increased the specificity of each analog for InhA. Both analogs had substantially longer half lives in serum, exhibited a 5-fold reduction in cytotoxicity compared to the parent compound, and were well tolerated when administered orally at 300mg/kg in animal models.
Introduction
Isoniazid (INH) is the single most effective chemotherapeutic for the treatment of tuberculosis. While the exquisite potency of INH may result from a complex mode of action that still remains to be completely delineated (15) , it is known that INH affects cell wall biosynthesis via alterations of the mycobacterial type II fatty acid biosynthesis (FAS-II) pathway, one mechanism of which is through inhibition of InhA, the FAS-II enoyl reductase (1, 13, 16, 20) .
Although INH resistance is associated with mutations in InhA, as well as KasA, and the upstream regulatory region of mabA-inhA operon (12, 16, 20) , the vast majority of INHresistance isolates contain mutations in the KatG catalase perioxidase protein responsible for the activation of INH (2, 9, 14, 16) . Consequently, novel compounds, with a distinct pharmacophore that inhibit InhA, but do not require activation by KatG, hold promise for the treatment of MDR clinical strains of M. tuberculosis.
Previously we reported on the synthesis of compounds designed to explore the diphenyl ether pharmacophore as a potential antitubercular agent. These studies were based on the known ability of triclosan to inhibit the enoyl reductase class of enzymes (21) . Using rational drug development strategies, this initial study substantiated the use of modeling, enzyme inhibition, and whole cell assays to identify compounds with enhanced activity against clinical strains of M. tuberculosis with varying drug resistance profiles. However, it did not address whole bacterial mode of action, toxicity or in vivo activity of the compounds. Accordingly, the work presented here expands on our previous report by investigation of the mode of action and potential detoxification transcriptional patterns of the most potent analogs identified, and analysis of their efficacy in models of infections. Our findings demonstrate that although these high affinity InhA inhibitors have low bioavailability issues, they are more effective in vitro inhibitors with lower cytotoxicity than the parent compound triclosan, thus narrowing the spectrum of structural changes required for drug enhancement. The transcriptional responses
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Materials and Methods
MIC determinations and cytotoxicity testing.
MIC values were determined using the microplate dilution method, as previously described (17) . African Green Monkey cells (Vero) were grown in RPMI 1640 medium supplemented with 1.5 g/L sodium bicarbonate, 10 mM sodium pyruvate, 140 mL/L 100 X non-essential amino acids, 100 mL/L penicillin/streptomycin solution and 10% bovine calf serum at 37 o C in a 5% CO 2 incubator and 75% humidity. Testing was conducted for 72 hours at 37°C in a 5% CO 2 incubator. Cells were washed, CellTiter 96 ® AQueous One
Solution was added to each well, and plates were incubated for 4 hours at 37°C. Plates were read at 490nm using a spectrophotometric plate reader and the absorbance readings were used to calculate lethal concentration 50% (LC 50 ).
Rapid Macrophage assay.
A rapid macrophage assay has been developed to assess the activity of compounds against intracellular bacteria. J774A.1 cells were allowed to phagocytose M. tuberculosis H37Rv (MOI of 1:10) for 4 hours at 37°C, then washed four times with PBS and culture growth media without (control) or containing either 6PP or 8PP at the MIC or 2 x MIC. At time zero, 1, and 4 days post infection, triplicate monolayers per compound were washed 4 times in PBS, lysed by the addition of 0.1% Triton X-100, and plated on 7H11 medium.
Following incubation at 37°C, colony forming units were enumerated.
In vivo evaluation. The oral bioavailability of the compounds was tested using a bioassay approach, as described before (8). Eight to ten week old female C57BL/6 mice were dosed via oral gavage. At 20 min., 1hr, 2hr and 4hr after dosing, 3 mice were bled from the tail vein.
Serum and standards of the compounds were tested using 3-fold dilutions against M.
tuberculosis H37Rv. Bacterial growth was determined by optical density after 3, 6, 9 and 12
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days. An estimation of serum drug levels (in µg ml -1 serum) was obtained by using the MIC data from the standard drug lanes.
Transcriptional profiling. M. tuberculosis H37Rv was treated with 15 µM 6PP, 12 µM 8PP, 86
µM triclosan, or left untreated at 37°C shaking for 2 hrs. Whole bacteria were subjected to trizol and total RNA was isolated by physical disruption. Microarray analysis was performed with labeled cDNA generated using direct labeling from 5 µg of total RNA as described (18) . The resulting fluorescence for each channel of the array (Cy3 and Cy5) was normalized by mean channel intensities and analyzed using Genesifter analysis software. T-test statistical analysis, and Benjamini and Hochberg correction was applied to all analyses on the all mean normalized data. Significance was considered to be >1.5 fold alteration in expression with a p-value cutoff of <0.05. Transcriptional activity of selected genes identified by DNA microarray analysis was verified using real time PCR as described (21) . values of 13 µg/mL and 10 µg/mL, resulting in a therapeutic index of 6 and 5, respectively. In contrast the parent compound which had an LC 50 at or below the MIC resulting in a measurable therapeutic index of 1.
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Assessment of serum binding and activity in the rapid macrophage assay. To evaluate whether protein binding alters the activity of 6PP and 8PP and whether they are able to inhibit the growth of intracellular M. tuberculosis, their MICs were determined in the presence of 10% mouse serum (according to NCCLS guidelines), and their activity against bacteria in the rapid macrophage assay was evaluated. The results showed that the MIC for 6PP or 8PP was not influenced by the presence of serum, indicating that neither of these compounds has serum binding problems (Table 2) . Furthermore, addition of 6PP or 8PP at 2 x MIC to macrophages . It should also be noted that both 6PP and 8PP displayed much lower toxicity in the macrophage assay than the parent compound, triclosan, which was lethal to the macrophages after one day of treatment at both MIC and 2 x MIC levels.
Bioavailability and In vivo efficacy of 6PP and 8PP.
As a prelude to more detailed in vivo studies, a bioavailability assay was performed to assess the serum levels of 6PP and 8PP after oral administration (8). Drug serum levels of 6PP and 8PP ranged from 66 to 132 µg/mL depending on the formulation (Table 2) , resulting in serum absorption indices from 18 to 40. This is in contrast to INH that had serum levels greater than 13 µg/mL resulting in a serum absorption index greater than 320. Importantly, the presence of analogs could be detected in the serum at 8 hours after dosing, which is much longer than that reported for INH (3).
Transcriptional differences between triclosan, 6PP, and 8PP. Previous reports indicate that
triclosan affects respiration in addition to fatty acid synthesis, which likely results because triclosan is only a modest InhA inhibitor and thus must be used at concentrations that elicit other cellular effects (6) . In order to determine if the increased potency of 6PP and 8PP towards InhA had narrowed the mode of action of these compounds, the global transcriptional response of H37Rv treated with 6PP, 8PP, or triclosan was assessed. These studies showed that triclosan had a more pleiotropic effect on bacterial metabolism than treatment with either 6PP or 8PP (Table 3, Tables S1, S2 ). In particular, 6PP and 8PP upregulated hallmark genes associated
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on October 25, 2017 by guest http://aac.asm.org/ Downloaded from with cell wall synthesis including fas, the KAS-operon, accD4, pks13, pks16, fadD32, and rv0241c (6), demonstrating that these compounds specifically target fatty acid biosynthesis. In contrast, triclosan failed to induce cell wall synthesis genes, rather this compound induced a large number of genes involved in β-oxidation including putative acyl-CoA synthases, acyl-CoA dehydrogenases that catalyze the initiation of β-oxidation, and genes that encode β-oxidation proteins responsible for cyclic degradation of fatty acids. In addition, 6PP and 8PP also induced genes involved in meromycolate modification (umaa, mmaa3,4), synthesis of arabinogalactan (embA,B) the final cell wall acceptor for mycolic acids and a member of the antigen 85 complex (fpbC) involved in deposition of mycolic acids (5).
Previously we reported that 6PP and 8PP failed to upregulate a putative efflux pump (rv1685c-1687c) and aromatic dioxygenase (rv3160c-rv3161c) that were induced by triclosan.
The additional studies reported here now show that instead 6PP and 8PP induce the expression of iniA,B,C, an operon reported to encode at least one component of an undefined efflux mechanism that is known to be induced by, and is associated with tolerance to the cell wall inhibitors isoniazid and ethambutol (7) . Thus, the diphenyl ether analogs circumvent detoxification mechanisms associated with triclosan, but may induce a potential efflux pump associated with drug tolerance. Furthermore, treatment with 6PP and 8PP consistently caused increased transcription of rv2846c (efpA), an efflux protein which when deleted in M. smegmatis leads to decreased susceptibility to INH (11). This particular efflux protein was not upregulated in M. tuberculosis following treatment with the parent compound, triclosan. These studies again raise important differences between triclosan and the alkyl-diphenyl ethers and also underline the similarity in transcriptional response between the latter and cell wall biosynthesis inhibitors such as INH. Table 4 and include genes encoding fatty acid and mycolic acid synthases. This provides a signature profile for identifying novel compounds that have a similar mode of action to 6PP and 8PP. An area of concern regarding the development of novel inhibitors against an established target is that these compounds might also be ineffective against existing drug resistant strains.
However by synthesizing high affinity InhA inhibitors that did not require KatG activation, both 6PP and 8PP were fully active against representative MDR clinical isolates with various resistance profiles. In addition, given the necessary long duration of treatment, toxicity is a significant issue with all anti-mycobacterial drugs. However, the A-ring modifications led to over a 5-fold reduction in cytotoxicity compared to triclosan.
Lower toxicity levels were also apparent upon treatment of macrophages: triclosan was toxic to macrophages, while 6PP and 8PP were not. Importantly, however, both 6PP and 8PP
showed the ability to reduce bacterial growth in the rapid macrophage assay, thus indicating that these compounds were able to enter the macrophage and remain effective against intracellular M. tuberculosis growing under altered metabolic conditions. Given orally, neither 6PP nor 8PP had bioavailability as high as that of INH, but the analogs could be detected at 8 hours post administration. In addition there were no adverse reactions noted upon oral The next step to optimizing drug activity of diphenyl ethers is to combine mechanistic and chemical information, so that physiochemical properties of diphenyl ethers can be modified for greater bioavailability without compromising the specificity. Previous studies have reported on the ability of signature transcriptional profiles to categorized drug classes based on metabolic pressure (6) . The identification of an increased number of genes allows for a greater number of features to be interrogated, thus providing a higher statistical significance to signature profiling of drug mode of action. Thus, next generation compounds will be subjected to high content multiple feature profiling to prioritize screening efforts to those analogs with improved in vivo properties that maintain the desired metabolic effect on the bacteria.
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6PP
2.1 ± 0.9 (7.8 ± 3.3)
18.8 ± 6.8 (69 ± 25)
2.9 ± 0.4 (10.7 ± 1.5) 2.0 ± 1.0 (7.4 ± 3.7)
3.1 ± 0 (11.5 ± 0) 3.7 ± 0.9 (13.7 ± 3.3)
3.1 ± 0 (11.5 ± 0) 12.5 6
8PP
1.9 ± 0.5 (6.4 ± 1.7)
22.9 ± 5.1 (77 ± 17) In vitro MIC values for H37Rv were determined within the bioavailability assay by microbroth dilution. 10% Serum was added to one set of controls to determine the effect of protein binding on the MIC value. Drug levels in the mouse serum were estimated by multiplying the dilution factor by the MIC value of the drug in the absence of serum. *The serum absorption index was calculated using serum conc. /MIC 99 and is a measure of bioavailability of the compound. c data formatted as total number of ORFs in category and (percentage compared to total differentially regulated ORFs). ORFs identified by tandem-SOM analysis and statistically analyzed using Genesifter software. ORFs in bold were confirmed by quantitative real time PCR from independent biological replicates. 
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